• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Aura Biosciences

Clearside Biomedical licenses microinjector to Aura Biosciences

July 9, 2019 By Brad Perriello

Clearside Biomedical

Clearside Biomedical (NSDQ:CLSD) said today that it licensed its microinjector technology to Aura Biosciences for use with Aura drug candidates in treating ocular cancers. Alpharetta, Ga.-based Clearside’s Suprachoroidal Space Microinjector is designed to deliver therapeutics into the suprachoroidal space between the sclera and choroid of the eye. Aura, based in Cambridge, Mass., is developing viral nanoparticle […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Research & Development Tagged With: Aura Biosciences, Clearside Biomedical

Aura Biosciences raises $30m for nanoparticle cancer treatment

December 21, 2017 By Sarah Faulkner

Aura Biosciences

Aura Biosciences has closed a $30 million Series C round with funding from new investors like Arix Bioscience and Lundbeckfonden Ventures, as well as existing investors, including the estate of former-Genzyme CEO Henri Termeer, who died earlier this year. The privately-held biotech is developing a light-activated nanoparticle therapy for patients with ocular melanoma. Aura said […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Nanoparticles, Oncology, Optical/Ophthalmic, Pharmaceuticals, Research & Development Tagged With: Aura Biosciences

Aura Biosciences wins fast track designation for light-activated nanoparticle therapy

March 30, 2017 By Sarah Faulkner

Aura Biosciences

Aura Biosciences said today that it enrolled and dosed the 1st patient in the Phase Ib trial of its light-activated AU-011 viral nanoparticle conjugate therapy for the treatment of ocular melanoma. The company also said that the FDA granted fast track designation to its targeted treatment, which will give priority review for the company’s New Drug […]

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Nanoparticles, Oncology, Optical/Ophthalmic, Regulatory/Compliance, Wall Street Beat Tagged With: Aura Biosciences

Aura Biosciences wins FDA nod for light-activated ocular melanoma treatment

February 6, 2017 By Sarah Faulkner

Aura Biosciences

Aura Biosciences said today that the FDA approved its Investigational New Drug Application for the company’s light-activated viral nanoparticle conjugates for the treatment of ocular melanoma. The federal watchdog’s approval allows Cambridge, Mass.-based Aura to move forward with initial clinical tests of AU-011. The Phase Ib open-label clinical trial, which is currently enrolling, is designed to […]

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Nanoparticles, Oncology, Optical/Ophthalmic, Regulatory/Compliance, Wall Street Beat Tagged With: Aura Biosciences

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS